Key result
Acetylcholinesterase inhibitors improved MMSE scores vs control at 6 months, with a greater effect in Parkinson/Lewy body dementia (2.11 points) than Alzheimer's/vascular dementia (0.91 points).
Why the study?
Do acetylcholinesterase inhibitors and memantine improve MMSE scores in patients with dementia?
Meta-Analysis
Do acetylcholinesterase inhibitors and memantine improve MMSE scores in patients with dementia?
Effect estimate: MD 2.11 for PDD/DLB and 0.91 for AD/VD
AChEIs demonstrate a modest, dementia subtype-dependent improvement in MMSE scores at 6 months, with a smaller effect seen for memantine.
Authors
No takes yet. Share an insight, caveat, or question.
Supports 6-month MMSE benefits of AChEIs and memantine; confirms efficacy with dementia subtype moderation.
Knight et al. (2018) conducted a meta-analysis in Dementia. Acetylcholinesterase inhibitors (AChEIs) and memantine vs. Control was evaluated on MMSE scores (MD 2.11 for PDD/DLB and 0.91 for AD/VD). Acetylcholinesterase inhibitors improved MMSE scores vs control at 6 months, with a greater effect in Parkinson/Lewy body dementia (2.11 points) than Alzheimer's/vascular dementia (0.91 points).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: